Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to
evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous
injection (COVID-HIG) in the treatment of patients with COVID-19.